130 related articles for article (PubMed ID: 2963864)
1. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors.
Ramos OF; Kai C; Yefenof E; Klein E
J Immunol; 1988 Feb; 140(4):1239-43. PubMed ID: 2963864
[TBL] [Abstract][Full Text] [Related]
2. Requirement of leukocytic cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets.
Ramos OF; Patarroyo M; Yefenof E; Klein E
J Immunol; 1989 Jun; 142(11):4100-4. PubMed ID: 2565929
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of NK cytotoxicity by antibody-C3b/iC3b heteroconjugates.
Yefenof E; Benizri R; Reiter Y; Klein E; Fishelson Z
J Immunol; 1990 Feb; 144(4):1538-43. PubMed ID: 2303717
[TBL] [Abstract][Full Text] [Related]
4. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
[TBL] [Abstract][Full Text] [Related]
5. Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments.
Ramos OF; Nilsson B; Nilsson K; Eggertsen G; Yefenof E; Klein E
Cell Immunol; 1989 Apr; 119(2):459-69. PubMed ID: 2522826
[TBL] [Abstract][Full Text] [Related]
6. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
[TBL] [Abstract][Full Text] [Related]
7. Elevated NK sensitivity of Raji cells carrying acceptor-bound C3 fragments.
Kai C; Sármay G; Ramos O; Yefenof E; Klein E
Cell Immunol; 1988 May; 113(2):227-34. PubMed ID: 3359489
[TBL] [Abstract][Full Text] [Related]
8. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
9. Alternative pathway of complement activation by stimulated T lymphocytes. II. Elevation of cytotoxic potential against complement receptor-carrying cell lines.
Ramos OF; Sármay G; Eggertsen G; Nilsson B; Klein E; Gergely J
Eur J Immunol; 1987 Jul; 17(7):975-9. PubMed ID: 3111863
[TBL] [Abstract][Full Text] [Related]
10. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).
Vetvicka V; Thornton BP; Wieman TJ; Ross GD
J Immunol; 1997 Jul; 159(2):599-605. PubMed ID: 9218574
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
Bonavida B; Lebow LT; Bradley TP
J Immunol; 1984 Feb; 132(2):594-8. PubMed ID: 6606675
[TBL] [Abstract][Full Text] [Related]
12. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
[TBL] [Abstract][Full Text] [Related]
13. Phagocytosis of serum-opsonized zymosan down-regulates the expression of CR3 and FcRI in the membrane of human monocytes.
Wolf HM; Mannhalter JW; Salzmann HC; Göttlicher J; Ahmad R; Eibl MM
J Immunol; 1988 Nov; 141(10):3537-43. PubMed ID: 2972775
[TBL] [Abstract][Full Text] [Related]
14. The low affinity 40,000 Fc gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing.
Perl A; Looney RJ; Ryan DH; Abraham GN
J Immunol; 1986 Jun; 136(12):4714-20. PubMed ID: 3011902
[TBL] [Abstract][Full Text] [Related]
15. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3.
Schlesinger LS; Bellinger-Kawahara CG; Payne NR; Horwitz MA
J Immunol; 1990 Apr; 144(7):2771-80. PubMed ID: 2108212
[TBL] [Abstract][Full Text] [Related]
16. Distinct functions of surface receptors in the induction of neutrophil-mediated cytotoxicity.
Cordier G; Samarut C; Revillard JP
Ann Immunol (Paris); 1981; 132D(1):3-14. PubMed ID: 7347555
[TBL] [Abstract][Full Text] [Related]
17. Studies on human blood lymphocytes with iC3b (type 3) complement receptors. I. Granular, Fc-IgG receptor positive and negative subsets in healthy subjects and patients with systemic lupus erythematosus.
Bakke AC; Gray JD; Abo W; Quismorio FP; Lash A; Cooper SM; Horwitz DA
J Immunol; 1986 Feb; 136(4):1253-9. PubMed ID: 2935574
[TBL] [Abstract][Full Text] [Related]
18. Increased infectivity of stationary-phase promastigotes of Leishmania donovani: correlation with enhanced C3 binding capacity and CR3-mediated attachment to host macrophages.
Wozencraft AO; Blackwell JM
Immunology; 1987 Apr; 60(4):559-63. PubMed ID: 2953670
[TBL] [Abstract][Full Text] [Related]
19. Alternative pathway of complement activation by stimulated T lymphocytes. I. Binding of C3 fragments.
Sármay G; Ramos OF; Klein E; Kai C; Gergely J
Eur J Immunol; 1987 Jul; 17(7):969-74. PubMed ID: 3111862
[TBL] [Abstract][Full Text] [Related]
20. Ligands of CR2 do not interfere with C3 fragment fixation or enhanced NK sensitivity of Raji cells treated with human serum.
Yefenof E; Ramos OF; Nilsson B; Klein E
Immunol Lett; 1989 Jun; 21(4):303-6. PubMed ID: 2527817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
